ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer
30. Juni 2016 07:00 ET
|
ArQule, Inc.
75% disease control rate, including a 25% objective response rate, was observed in 12 evaluable patients harboring FGFR2 genetic alterations BURLINGTON, Mass., June 30, 2016 (GLOBE NEWSWIRE) --...
ArQule to Present Preliminary Phase 1/2 Data for FGFR Inhibitor, ARQ 087, in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer
23. Juni 2016 07:00 ET
|
ArQule, Inc.
BURLINGTON, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that preliminary data from the ongoing phase 2 portion of a phase 1/2 trial in intrahepatic...